Cargando…
Remission of severe myasthenia gravis after autologous stem cell transplantation
OBJECTIVE: Myasthenia gravis (MG) is an autoantibody‐mediated neuromuscular junction disorder involving the acetylcholine receptors on the motor endplate. The safety and response to high‐dose chemotherapy (HDIT) and autologous hematopoietic cell transplantation (HCT) were assessed in a patient with...
Autores principales: | Schlatter, Monica I., Yandamuri, Soumya S., O'Connor, Kevin C., Nowak, Richard J., Pham, Minh C., Obaid, Abeer H., Redman, Callee, Provost, Marie, McSweeney, Peter A., Pearlman, Michael L., Tees, Michael T., Bowen, James D., Nash, Richard A., Georges, George E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646993/ https://www.ncbi.nlm.nih.gov/pubmed/37726935 http://dx.doi.org/10.1002/acn3.51898 |
Ejemplares similares
-
Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis
por: Obaid, Abeer H., et al.
Publicado: (2022) -
Clinical Characteristics of Refractory Myasthenia Gravis
Patients
por: Suh, Joome, et al.
Publicado: (2013) -
Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology
por: Fichtner, Miriam L., et al.
Publicado: (2020) -
Myasthenia gravis complement activity is independent of autoantibody titer and disease severity
por: Fichtner, Miriam L., et al.
Publicado: (2022) -
Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)